scholarly journals A retrospective study on the effectiveness of Artificial Intelligence-based Clinical Decision Support System (AI-CDSS) to improve the incidence of hospital-related venous thromboembolism (VTE)

2021 ◽  
Vol 9 (6) ◽  
pp. 491-491
Author(s):  
Shuai Zhou ◽  
Xudong Ma ◽  
Songyi Jiang ◽  
Xiaoyan Huang ◽  
Yi You ◽  
...  
2019 ◽  
Vol 42 (3) ◽  
pp. 771-779 ◽  
Author(s):  
Tayyebe Shabaniyan ◽  
Hossein Parsaei ◽  
Alireza Aminsharifi ◽  
Mohammad Mehdi Movahedi ◽  
Amin Torabi Jahromi ◽  
...  

2017 ◽  
Vol 24 (2) ◽  
pp. 33-40 ◽  
Author(s):  
Galila F. Zaher ◽  
Soheir S. Adam

Venous thromboembolism is a serious but potentially preventable condition. However, morbidity and mortality occur due to lack of thrombo-prophylaxis. Obstetrics and gynecology patients are at risk for developing venous thromboembolism. To improve adherence to thromboprophylaxis in this patient population, we developed a smart phone clinical decision support system designed to assess risk score and recommend thromboprophylaxis. Clinical data were collected by review of electronic medical charts. The risk score and thromboprophylaxis recommendations were calculated for each patient by clinical decision support system and by an expert hematologist and results were compared for correlation. We hypothesize that the system is a valid tool for risk assessment in obstetrics and gynecology patients. A total of 188 female patients admitted at King Abdulaziz University Hospital between December 2015 and March 2016 were included. One hundred and sixteen were gynecology, and 72 were obstetric patients with a mean age of 40.7 (± 12.8). The risk score obtained by the system showed a strong correlation with that of the expert hematologist’s opinion (r = 83%). The clinical decision support system showed a good correlation for thromboprophylaxis decision as well. Accessibility and ease of use of clinical decision support system can improve the clinical outcome of hospitalized patients.


2021 ◽  
Author(s):  
Christina Popescu ◽  
Grace Golden ◽  
David Benrimoh ◽  
Myriam Tanguay-Sela ◽  
Dominique Slowey ◽  
...  

Objective: We examine the feasibility of an Artificial Intelligence (AI)-powered clinical decision support system (CDSS), which combines the operationalized 2016 Canadian Network for Mood and Anxiety Treatments guidelines with a neural-network based individualized treatment remission prediction. Methods: Due to COVID-19, the study was adapted to be completed entirely at a distance. Seven physicians recruited outpatients diagnosed with major depressive disorder (MDD) as per DSM-V criteria. Patients completed a minimum of one visit without the CDSS (baseline) and two subsequent visits where the CDSS was used by the physician (visit 1 and 2). The primary outcome of interest was change in session length after CDSS introduction, as a proxy for feasibility. Feasibility and acceptability data were collected through self-report questionnaires and semi-structured interviews. Results: Seventeen patients enrolled in the study; 14 completed. There was no significant difference between appointment length between visits (introduction of the tool did not increase session length). 92.31% of patients and 71.43% of physicians felt that the tool was easy to use. 61.54% of the patients and 71.43% of the physicians rated that they trusted the CDSS. 46.15% of patients felt that the patient-clinician relationship significantly or somewhat improved, while the other 53.85% felt that it did not change. Conclusions: Our results confirm the primary hypothesis that the integration of the tool does not increase appointment length. Findings suggest the CDSS is easy to use and may have some positive effects on the patient-physician relationship. The CDSS is feasible and ready for effectiveness studies.


2021 ◽  
Author(s):  
Christina Popescu ◽  
Grace Golden ◽  
David Benrimoh ◽  
Myriam Tanguay-Sela ◽  
Dominique Slowey ◽  
...  

BACKGROUND Approximately two thirds of patients with major depressive disorder (MDD) do not achieve remission during their first treatment. There has been increasing interest in the use of digital, artificial intelligence (AI)-powered clinical decision support systems (CDSS) to assist physicians in their treatment selection and management, improving personalization and use of best practices such as measurement-based care. Previous literature shows that in order for digital mental health tools to be successful, the tool must be easy to use for patients and physicians and feasible within existing clinical workflows. OBJECTIVE We examine the feasibility of an AI-powered clinical decision support system, which combines the operationalized 2016 Canadian Network for Mood and Anxiety Treatments guidelines with a neural-network based individualized treatment remission prediction. METHODS Due to COVID-19, the study was adapted to be completed entirely at a distance. Seven physicians recruited outpatients diagnosed with MDD as per DSM-V criteria. Patients completed a minimum of one visit without the CDSS (baseline) and two subsequent visits where the CDSS was used by the physician (visit 1 and 2). The primary outcome of interest was change in session length after CDSS introduction, as a proxy for feasibility. Feasibility and acceptability data were collected through self-report questionnaires and semi-structured interviews. RESULTS Seventeen patients enrolled in the study; 14 completed. There was no significant difference between appointment length between visits (introduction of the tool did not increase session length). 92.31% of patients and 71.43% of physicians felt that the tool was easy to use. 61.54% of the patients and 71.43% of the physicians rated that they trusted the CDSS. 46.15% of patients felt that the patient-clinician relationship significantly or somewhat improved, while the other 53.85% felt that it did not change. CONCLUSIONS Our results confirm the primary hypothesis that the integration of the tool does not increase appointment length. Findings suggest the CDSS is easy to use and may have some positive effects on the patient-physician relationship. The CDSS is feasible and ready for effectiveness studies. CLINICALTRIAL NCT04061642


JAMA ◽  
2000 ◽  
Vol 283 (21) ◽  
pp. 2816 ◽  
Author(s):  
Pierre Durieux ◽  
Rémy Nizard ◽  
Philippe Ravaud ◽  
Nicolas Mounier ◽  
Eric Lepage

2021 ◽  
Author(s):  
Myriam Tanguay-Sela ◽  
David Benrimoh ◽  
Christina Popescu ◽  
Tamara Perez ◽  
Colleen Rollins ◽  
...  

AbstractAifred is a clinical decision support system (CDSS) that uses artificial intelligence to assist physicians in selecting treatments for major depressive disorder (MDD) by providing probabilities of remission for different treatment options based on patient characteristics. We evaluated the utility of the CDSS as perceived by physicians participating in simulated clinical interactions. Twenty psychiatry and family medicine staff and residents completed a study in which each physician had three 10-minute clinical interactions with standardized patients portraying mild, moderate, and severe episodes of MDD. During these scenarios, physicians were given access to the CDSS, which they could use in their treatment decisions. The perceived utility of the CDSS was assessed through self-report questionnaires, scenario observations, and interviews. 60% of physicians perceived the CDSS to be a useful tool in their treatment-selection process, with family physicians perceiving the greatest utility. Moreover, 50% of physicians would use the tool for all patients with depression, with an additional 35% noting they would reserve the tool for more severe or treatment-resistant patients. Furthermore, clinicians found the tool to be useful in discussing treatment options with patients. The efficacy of this CDSS and its potential to improve treatment outcomes must be further evaluated in clinical trials.


Sign in / Sign up

Export Citation Format

Share Document